Against the backdrop of increasing global demand for anticancer drugs, the Laos Dabear version of Axitinib, with its relatively accessible cost and standardized generic manufacturing process, has become an important alternative option for many patients in multi-line therapy.
How much does the Laos Dabear version of Axitinib cost?
The Laos Dabear version of Axitinib is available in a specification of 5mg*30 tablets/box, at a price of approximately $70. The specific price may be affected by various factors and should be based on the actual selling price.
Overdose and management of Axitinib
There is currently no specific antidote or standard treatment regimen for axitinib overdose. In clinical studies, one renal cancer patient who accidentally took a dose of 20mg twice daily for 4 days experienced grade 1 dizziness. Additionally, in a dose-finding study, subjects receiving starting doses of 10mg or 20mg twice daily experienced more severe adverse reactions, including hypertension, seizure associated with hypertension, and even fatal hemoptysis. Therefore, if overdose is suspected, axitinib should be discontinued immediately and active supportive care should be provided, such as blood pressure control, fluid replacement, and symptomatic treatment. Patients must strictly follow medical advice during use and should not increase the dose on their own. If a dose is missed, the next dose should be taken at the scheduled time without doubling up. Populations at higher risk of overdose include those with impaired liver function, those taking concomitant CYP3A4/5 inhibitors, and the elderly.
Contraindications and high-risk drug combinations for Axitinib
Axitinib should be avoided in combination with strong CYP3A4/5 inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir, etc. If concomitant use is clinically unavoidable, the axitinib dose should be reduced by approximately half and patients should be closely monitored for adverse reactions. Concurrent use with strong CYP3A4/5 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort, etc.) should also be avoided, as these drugs can significantly reduce axitinib plasma concentrations and affect efficacy. Before using axitinib, patients should inform their doctor of all medications they are taking, including prescription drugs, over-the-counter drugs, traditional Chinese medicines, and supplements, to avoid potential drug interactions. Furthermore, axitinib is not recommended for patients with untreated brain metastases or those with recent evidence of active gastrointestinal bleeding, as its safety and efficacy have not been established in these populations.
